Beamtree Holdings Ltd (AU:BMT)
ASX:BMT
Want to see AU:BMT full AI Analyst Report?
Top Page
Beamtree Holdings Ltd
(Sydney:BMT)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.12
▼(-47.27% Downside)
Action:ReiteratedDate:02/21/26
The score is primarily driven down by weak financial performance (loss-making operations, negative revenue growth, and cash flow strain) and bearish technical momentum (price below key moving averages with negative MACD). Valuation is only modestly supportive because the negative P/E reflects current losses and dividend yield is unavailable.
Positive Factors
Balance sheet conservatism
A relatively low debt-to-equity ratio provides durable financial flexibility: with conservative leverage the company has lower fixed interest obligations and more capacity to fund operations, R&D, or strategic initiatives over the next 2-6 months without immediate refinancing pressure.
Negative Factors
Negative profitability
Sustained negative EBIT/EBITDA margins indicate the business is not generating operating profits; this undermines internal funding for growth and increases reliance on external capital. Over 2-6 months continued operating losses can compress strategic options and delay path to sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet conservatism
A relatively low debt-to-equity ratio provides durable financial flexibility: with conservative leverage the company has lower fixed interest obligations and more capacity to fund operations, R&D, or strategic initiatives over the next 2-6 months without immediate refinancing pressure.
Read all positive factors
Beamtree Holdings Ltd (BMT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$34.88M
Dividend YieldN/A
Average Volume (3M)122.51K
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue Growth0.03%
EPS Growth-5.85%
CountryAU
Employees97
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.02
Shares Outstanding290,696,170
10 Day Avg. Volume152,204
30 Day Avg. Volume122,509
Financial Highlights & Ratios
PEG Ratio-0.66
Price to Book (P/B)1.72
Price to Sales (P/S)2.53
P/FCF Ratio-39.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.30Price Target Upside36.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$31.40M
Beamtree Holdings Ltd Business Overview & Revenue Model
Company Description
Beamtree Holdings Limited develops and commercializes clinical decision support (CDS) systems to healthcare industry in Australia and internationally. The company offers RippleDown Expert, a CDS system that provides real-time patient monitoring an...
How the Company Makes Money
null...
Beamtree Holdings Ltd Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.90M | 28.60M | 27.60M | 22.77M | 16.55M | 8.39M |
| Gross Profit | 1.66M | 28.60M | 4.89M | 2.14M | -202.00K | 2.77M |
| EBITDA | -4.74M | -808.00K | -331.00K | -1.26M | -2.28M | 1.02M |
| Net Income | -5.78M | -6.16M | -5.11M | -6.91M | -4.45M | -383.62K |
Balance Sheet | ||||||
| Total Assets | 53.26M | 54.29M | 59.65M | 62.53M | 63.91M | 47.05M |
| Cash, Cash Equivalents and Short-Term Investments | 2.94M | 4.78M | 5.04M | 8.81M | 6.35M | 14.12M |
| Total Debt | 3.65M | 3.26M | 1.66M | 755.00K | 1.12M | 799.36K |
| Total Liabilities | 13.76M | 12.36M | 12.52M | 15.31M | 15.33M | 4.96M |
| Stockholders Equity | 39.51M | 41.93M | 47.14M | 47.22M | 48.58M | 42.09M |
Cash Flow | ||||||
| Free Cash Flow | 906.00K | -1.84M | -4.51M | -1.88M | -4.83M | -2.64M |
| Operating Cash Flow | 1.08M | 609.00K | -492.00K | 768.00K | -2.32M | 240.65K |
| Investing Cash Flow | -3.37M | -2.45M | -4.02M | -2.65M | -5.16M | -2.98M |
| Financing Cash Flow | 1.54M | 1.58M | 749.00K | 4.34M | -286.00K | 12.65M |
Beamtree Holdings Ltd Technical Analysis
Negative
0.22
Price Trends
0.15
Negative
0.18
Negative
0.20
Negative
Market Momentum
>-0.01
Negative
40.98
Neutral
63.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BMT, the sentiment is Negative. The current price of 0.22 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.15, and above the 200-day MA of 0.20, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.98 is Neutral, neither overbought nor oversold. The STOCH value of 63.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BMT.
Beamtree Holdings Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$134.30M | 26.51 | 4.37% | ― | 36.43% | ― | |
55 Neutral | AU$22.90M | 3.95 | 7.57% | ― | 31.36% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$62.28M | -6.28 | -23.86% | ― | -11.45% | -97.22% | |
44 Neutral | AU$34.88M | -5.70 | -14.19% | ― | 0.03% | -5.85% | |
43 Neutral | AU$30.31M | -3.13 | -1009.84% | ― | 13.69% | 7.57% |
* Healthcare Sector Average
AU:BMT
Beamtree Holdings Ltd
0.12
-0.09
-42.86%
AU:M7T
Mach7 Technologies
0.27
-0.08
-23.19%
AU:RHT
Resonance Health Ltd
0.05
0.01
33.33%
AU:ALC
Alcidion Group Limited
0.10
0.02
25.00%
AU:PCK
PainChek Ltd
0.15
-0.24
-61.84%
Beamtree Holdings Ltd Corporate Events
Beamtree Seeks ASX Quotation for New Employee Incentive Shares
Apr 28, 2026
Beamtree Holdings has applied for quotation on the ASX of 52,954 new ordinary fully paid shares issued to employees under its Employee Incentive Plan. The shares were allotted on 28 April 2026 as part of salary contribution arrangements, reinforci...
Beamtree Appoints Martin Bowles to Board Without Equity Stake
Mar 9, 2026
Beamtree Holdings Limited has announced the appointment of Martin Bowles as a director, effective 2 March 2026, and lodged the required initial director’s interest notice with the ASX. The filing confirms that Bowles currently holds no relev...
Mirrabooka Exits Substantial Holder Position in Beamtree After Corrected Filing
Mar 4, 2026
Mirrabooka Investments Limited has notified Beamtree Holdings Limited that it has ceased to be a substantial holder in the company as of 3 March 2026. The change was communicated through a corrected statutory notice, replacing an earlier version l...
Mirrabooka exits substantial holding in Beamtree Holdings
Mar 4, 2026
Mirrabooka Investments Limited has notified Beamtree Holdings Limited that it has ceased to be a substantial shareholder as of 3 March 2026, in line with Australian disclosure rules for significant holdings. The move follows a series of trades whe...
Beamtree Reshapes Board and Pay Structure as Strategic Review Begins
Mar 1, 2026
Beamtree Holdings has reshaped its governance structure as it undertakes a strategic review aimed at unlocking shareholder value, with Chair Emma Gray stepping into a time-limited Executive Chair role to oversee the process while CEO Marek Stepnia...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.